6505--Budesonide/Formoterol INH

The solicitation seeks offers for commercial pharmaceutical products and related services (including active ingredients, tablets, capsules, sterile products, other dosage forms, packaging, and repackaging) under a base‑year contract with a five‑year option. Offerors must submit a complete subcontracting plan that complies with FAR 52.219‑9, providing dollar and percentage goals for each option period, justification for any goal lower than the VA‑suggested or prior‑year achieved level, and a detailed list of specific source‑identification methods (websites, associations, events, etc.). The plan must indicate whether indirect costs are included, state total projected subcontract spend (including both large and small businesses), and align with the contractor’s fiscal year (individual plan) or company/division fiscal year (commercial plan). All proposals must include the offeror’s UEI and CAGE code, a unique 11‑digit NDC for each line item, and meet the packaging requirements in the scope. Prices must cover the base year plus four option years and incorporate a 0.5 % cost‑recovery fee. Offerors must certify compliance with FAR 52.209‑7, 52.219‑1, and 52.225‑6, and confirm that every covered drug product/NDC is listed on the offeror’s FSS contract or interim agreement with an established Permanent FCP by the offer due date; non‑compliant offers will be rejected. Quarterly sales reports in U.S. dollars are required, and the contract is set aside for multiple small‑business categories ( HUBZone, Service‑Disabled Veteran‑Owned, Women‑Owned, etc.). Offerors must also identify the exact manufacturing facilities (address, FEI, contact) and indicate whether they are the manufacturer or a distributor, ensuring compliance with cGMP and VA’s substantial‑transformation criteria.

Notice ID

78a58b5adadd43869410fcb8070171df

Solicitation Number

36E79726R0013

NAICS Code

325412

Classification Code

6505